
Cellectis S.A. CLLS
€ 3.07
2.57%
Geschäftsbericht 2025
hinzugefügt 11.04.2026
Cellectis S.A. P/S 2011-2026 | CLLS
P/S Jährlich Cellectis S.A.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 6.69 | 17.9 | 47.1 | 64.3 | 46.2 | 11.5 | 13.9 | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 64.3 | 6.69 | 29.7 |
P/S anderer Aktien in der Pharmaeinzelhändler
| Name | P/S | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 | - | - | $ 86.2 M | ||
|
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | ||
|
Nanobiotix S.A.
NBTX
|
98.9 K | $ 30.34 | -0.82 % | $ 286 B | ||
|
I-Mab
IMAB
|
94.1 | - | - | $ 866 M | ||
|
Akebia Therapeutics
AKBA
|
1.42 | $ 1.4 | -0.71 % | $ 360 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.96 K | - | 2.54 % | $ 160 B | ||
|
Applied Therapeutics
APLT
|
54.1 | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
6.61 | - | -13.39 % | $ 1.45 M | ||
|
BioNTech SE
BNTX
|
35.7 | $ 95.5 | 3.83 % | $ 27.2 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
759 | $ 2.92 | -0.34 % | $ 6.35 B | ||
|
Aytu BioScience
AYTU
|
0.237 | $ 2.55 | -0.78 % | $ 16 M | ||
|
Midatech Pharma plc
MTP
|
137 | - | -18.52 % | $ 27.3 M | ||
|
AstraZeneca PLC
AZN
|
2.17 | - | - | $ 96.9 B | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.73 | $ 20.37 | -2.4 % | $ 952 M | ||
|
Aquestive Therapeutics
AQST
|
10.5 | $ 4.08 | -2.16 % | $ 436 M | ||
|
Ayala Pharmaceuticals
AYLA
|
11.2 | - | - | $ 7.46 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - | ||
|
Arcutis Biotherapeutics
ARQT
|
9.15 | $ 24.21 | -1.47 % | $ 3.08 B | ||
|
BeiGene, Ltd.
BGNE
|
66.4 | - | 0.49 % | $ 251 B | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | ||
|
Celldex Therapeutics
CLDX
|
1.32 K | $ 32.24 | -4.1 % | $ 2.14 B | ||
|
Aeglea BioTherapeutics
AGLE
|
489 | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
CymaBay Therapeutics
CBAY
|
110 | - | - | $ 3.45 B | ||
|
AIkido Pharma
AIKI
|
0.935 | - | 1.93 % | $ 17.4 M | ||
|
Cabaletta Bio
CABA
|
50.3 M | $ 3.13 | -1.26 % | $ 315 M | ||
|
Codiak BioSciences
CDAK
|
10.5 | - | -55.98 % | $ 2.15 M | ||
|
Avid Bioservices
CDMO
|
3.03 | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
116 | - | - | $ 1.41 B | ||
|
Immutep Limited
IMMP
|
492 | $ 0.31 | -2.52 % | $ 1.08 B | ||
|
Checkpoint Therapeutics
CKPT
|
3.91 K | - | - | $ 169 M | ||
|
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | ||
|
Concert Pharmaceuticals
CNCE
|
41.3 | - | - | $ 401 M | ||
|
Celsion Corporation
CLSN
|
26.1 | - | -6.63 % | $ 13.9 M |